ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.691,32
0,05%
S&P 500
5.265,23
-0,79%
Dow Jones
39.050,47
-1,56%
Euro vs US Dollar
1,08085
-0,15%
Bitcoin
67.197,74
-2,76%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ENDRA Life Sciences Inc (NDRA)

  7. ENDRA Life Sciences Inc (NDRA) News

NDRA

ENDRA Life Sciences (NDRA)

ENDRA Life Sciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NDRA
DatumZeitQuelleÜberschriftSymbolFirma
20/05/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
20/05/202414h00Business WireENDRA Provides Update Following In-person Meeting with FDANASDAQ:NDRAENDRA Life Sciences Inc
14/05/202422h26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NDRAENDRA Life Sciences Inc
14/05/202422h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
14/05/202422h05Business WireENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
10/05/202423h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
10/05/202423h17Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:NDRAENDRA Life Sciences Inc
07/05/202414h00Business WireENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024NASDAQ:NDRAENDRA Life Sciences Inc
02/05/202414h00Business WireENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International PatentsNASDAQ:NDRAENDRA Life Sciences Inc
28/03/202421h05Business WireENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
21/03/202413h00Business WireENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024NASDAQ:NDRAENDRA Life Sciences Inc
27/02/202414h00Business WireENDRA Life Sciences Installs First TAEUS System in the UKNASDAQ:NDRAENDRA Life Sciences Inc
23/02/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NDRAENDRA Life Sciences Inc
21/02/202414h00Business WireNew ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS SystemNASDAQ:NDRAENDRA Life Sciences Inc
14/02/202414h30Business WireENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and EuropeNASDAQ:NDRAENDRA Life Sciences Inc
29/12/202323h07Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NDRAENDRA Life Sciences Inc
29/11/202314h00Business WireENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System TechnologyNASDAQ:NDRAENDRA Life Sciences Inc
27/11/202314h00Business WireENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor ConferenceNASDAQ:NDRAENDRA Life Sciences Inc
14/11/202322h05Business WireENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
14/11/202322h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
08/11/202314h00Business WireENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New PatentsNASDAQ:NDRAENDRA Life Sciences Inc
07/11/202322h05Business WireENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:NDRAENDRA Life Sciences Inc
06/11/202314h00Business WireENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023NASDAQ:NDRAENDRA Life Sciences Inc
07/09/202314h00Business WireAbstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023NASDAQ:NDRAENDRA Life Sciences Inc
30/08/202314h00Business WireENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDANASDAQ:NDRAENDRA Life Sciences Inc
23/08/202314h00Business WireENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European PatentsNASDAQ:NDRAENDRA Life Sciences Inc
14/08/202322h53Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NDRAENDRA Life Sciences Inc
14/08/202322h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NDRAENDRA Life Sciences Inc
14/08/202322h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
14/08/202322h05Business WireENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:NDRA

Kürzlich von Ihnen besucht

COIN
THXXXETH
THX Network
EU
DEUAN
Departement de lEure Dom...
BIT
P20U48
NLBNPIT20U48 20991231 33...
FX
EURINR
Euro vs INR
TG
OMV
OMV
AQSE
VWRD.GB
Vanguard Ftse Allworld U...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten